These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34661604)

  • 21. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
    Benjamin DJ; Xu A; Lythgoe MP; Prasad V
    JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
    Chen EY; Joshi SK; Tran A; Prasad V
    JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011.
    Shih YC; Smieliauskas F; Geynisman DM; Kelly RJ; Smith TJ
    J Clin Oncol; 2015 Jul; 33(19):2190-6. PubMed ID: 25987701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
    Marquart J; Chen EY; Prasad V
    JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
    Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
    Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy.
    Ranganathan S; Haslam A; Tuia J; Prasad V
    J Cancer Policy; 2024 Mar; 39():100462. PubMed ID: 38061492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
    Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
    Olivier T; Haslam A; Prasad V
    JAMA Netw Open; 2021 Dec; 4(12):e2138793. PubMed ID: 34905002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022.
    Mousavi I; Olivier T; Prasad V
    JAMA Netw Open; 2022 Jun; 5(6):e2216058. PubMed ID: 35687338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
    Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
    Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.
    Jiang DM; Chan KKW; Jang RW; Booth C; Liu G; Amir E; Mason R; Everest L; Elimova E
    Cancer Med; 2019 Apr; 8(4):1584-1593. PubMed ID: 30848108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
    Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
    JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit.
    Rotenstein LS; Dusetzina SB; Keating NL
    J Manag Care Spec Pharm; 2018 Jun; 24(6):494-502. PubMed ID: 29799324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
    Hilal T; Sonbol MB; Prasad V
    JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan.
    Maeda H; Shingai R; Takeda K; Hara A; Murai Y; Ofuchi M
    JAMA Netw Open; 2023 Apr; 6(4):e238875. PubMed ID: 37115550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
    Michaeli DT; Michaeli T
    J Clin Oncol; 2022 Dec; 40(35):4095-4106. PubMed ID: 35921606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
    Chen EY; Raghunathan V; Prasad V
    JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures.
    Tisdale RL; Ma I; Vail D; Bhattacharya J; Goldhaber-Fiebert JD; Heidenreich PA; Sandhu AT
    JAMA Netw Open; 2021 Jun; 4(6):e2113969. PubMed ID: 34143189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.